Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 9, 2025, and filed on October 10, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than providing comprehensive financial statements (revenue, profit, or cash flow). Key metrics for the transaction are as follows:
- Shares Purchased: 295,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,628.00p; highest price paid was 1,647.50p.
- Average Price: Volume-weighted average price paid was 1,640.23p.
- Treasury Holdings: Following this purchase, the Company holds 250,013,844 ordinary shares in treasury.
- Shares in Issue: 4,065,394,695 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.15% of total voting rights.
Material Changes and Programme Progress
Since the commencement of the current non-discretionary agreement on September 30, 2025, the Company has purchased an aggregate of 2,549,000 ordinary shares. The October 9 transaction represents a continuation of this programme. The filing does not disclose material changes to the Company's overall financial position, debt levels, or liquidity beyond the cash outflow associated with this specific buyback.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q2 Results for 2025. No unusual items or contingencies were disclosed in this specific report.
Important Facts for Investor Verification
- Verify the total remaining authorization under the current buyback programme to assess future capital return capacity.
- Confirm the impact of the 6.15% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the September 30, 2025 announcement to understand the total scope and duration of the non-discretionary agreement with BNP Paribas SA.
- Note that this filing does not contain revenue or profit data; refer to the most recent Form 20-F or quarterly results for operational performance.